Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 4/20 | 0.41 |
| ▸ | CNR2 | P34972 | 4/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.40 |
| ▸ | ICMT | O60725 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.40 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6065017 | 0.84 | LIPG (0.54) | LIPGCYSLTR2CYSLTR1 | |
| SCHEMBL7532688 | 0.73 | KDM4E (0.49) | EPHX1EPHX2KMT2ACNR1CNR2 | |
| SCHEMBL5509741 | 0.71 | CYSLTR2 (0.56) | LIPGCYSLTR2CYSLTR1 | |
| SCHEMBL11444088 | 0.71 | LIPG (0.56) | LIPGCYSLTR2CYSLTR1 | |
| SCHEMBL8080347 | 0.71 | CYSLTR2 (0.56) | LIPGCYSLTR2CYSLTR1 | |
| SCHEMBL5346786 | 0.71 | LIPG (0.56) | LIPGCYSLTR2CYSLTR1 | |
| SCHEMBL8086516 | 0.71 | CYSLTR2 (0.56) | LIPGCYSLTR2CYSLTR1 | |
| SCHEMBL8086397 | 0.71 | CYSLTR2 (0.56) | LIPGCYSLTR2CYSLTR1 | |
| SCHEMBL9559902 | 0.71 | CYSLTR2 (0.56) | LIPGCYSLTR2CYSLTR1 | |
| SCHEMBL10533245 | 0.71 | CYSLTR2 (0.56) | LIPGCYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247458-A1 | Process for the production of optically active compounds having substituents at the 2-position | KANEKA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
| EP-1600438-A1 | PROCESSES FOR THE PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS HAVING SUBSTITUENTS AT THE 2-POSITION | KANEKA CORPORATION (JP) | 2005-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247458-A1 | Process for the production of optically active compounds having substituents at the 2-position | TST, TMT1A, OSGEP | EPHX1 1356/4885EPHX2 475/4885KMT2A 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.